Endocrine-based therapies such as tamoxifen and aromatase inhibitors remain the most utilized and effective class of drugs for the treatment of ERα-positive breast cancer but are not used to treat TNBC due to lack of ERα expression. Here, ESR1 is linked to breast carcinoma.